Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have chronic kidney disease with a reduced kidney filtering rate (eGFR below 60 mL/min/1.73 m²)
- People who have a new blockage in a coronary artery that is suitable for treatment with a specific type of metal heart stent, and where a special imaging technique called IVUS can be used during the procedure
- People who have signed a written consent form agreeing to take part
Who may not be able to join:
- People who have had a severe heart attack (STEMI) within the last 24 hours, or who need emergency heart artery imaging
- People who are pregnant or who are able to become pregnant
- People with another serious illness where life expectancy is estimated at less than one year
- People whose heart pumping function is very low (heart pumping strength of 30% or less)
- People who are in cardiogenic shock or whose circulation is unstable
- People with severe liver problems, defined as certain liver enzyme levels more than five times the normal upper limit
- People who have had a heart stent procedure within the past 12 months
- People where the target artery blockage involves a previously placed stent or a stent that has re-narrowed
- People who have any non-heart surgery planned within the next 12 months
- People who are unable to follow the study requirements or attend follow-up visits, or where the study doctor feels participation would increase their risk
- People who are currently enrolled in another clinical trial
- People for whom blood-thinning anti-platelet medications are not medically appropriate
- People with a history of bleeding in the brain or digestive system that required a blood transfusion or surgery to control (not including haemorrhoids)
- People with a fully blocked artery where a guidewire could not be passed through successfully
- People currently taking certain medications that can harm the kidneys, such as some anti-inflammatory drugs (excluding low-dose aspirin), aminoglycosides, amphotericin B, polymyxin, or platinum-based drugs
- People whose kidney disease is caused by an immune or inflammatory condition, or who are currently on hormone (steroid) therapy for such a condition (for example, lupus nephritis or IgA nephropathy)
- People who are expected to receive contrast dye within 72 hours after the procedure, or who have already received contrast dye in a vein or artery within the previous 5 days
- People who are currently taking blood-thinning anticoagulant medications
- People with a very low haemoglobin level (below 60 g/L), indicating severe anaemia
- People with serious heart valve disease, or heart valve disease likely to need surgery or a valve replacement procedure during the trial period
- People who have a known allergy to metals or to contrast dye used in imaging
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ning Guo, The First Affiliated of Xi'an Jiaotong University
Phone: +86 13991229101
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Target vessel failure (TVF), including cardiac death, target vessel myocardial infarction (MI), or clinically driven target vessel revascularization (TVR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.